entertainment -WSS

entertainment

author：hotspot 2025-09-27 12:35:04 - browse：8143

The FDA building -- First Opinion coverage from STAT — Adobe

U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people to grow bone where it otherwise shouldn’t be, extending an option to patients who have been advocating for access to the medicine.

The treatment, an oral medication that will be marketed as Sohonos, faced some questions about the quality of its data, and was rejected earlier this year by European regulators. But in approving the drug for the treatment of fibrodysplasia ossificans progressiva, or FOP, the Food and Drug Administration concluded that Sohonos’ benefits outweigh its risks.

“I just closed my eyes and looked up to the skies, like ‘Thank you, God,’” said Suzanne Hollywood, whose teenage son, Joey, has been receiving the drug in a clinical trial. “It’s far from perfect, but I’m thrilled for my son, for his future, and for the kids getting diagnosed who might not have to experience what others had to.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Families look for replacement for GSK asthma drug Flovent

WSS

Fetal cell organoids grown from amniotic fluid, study finds

Microsoft's Peter Lee: Generative AI could help doctors be more human

For AI in health care standards, federal regulators join with industry group

Ozempic has benefits for kidney disease as well as diabetes

Sanofi seeks simpler, safer CRISPR sickle cell cure

Biden's 'march

focus

entertainment

focus

Medical leaders decry Supreme Court decision on affirmative action

Why Talkspace is targeting Medicare, a tricky market

Medicare details structure of new drug price negotiation program

Pregnant women don't need prenatal multivitamins, study concludes

Medicare proposal to cover medical devices draws a mixed reaction

Microsoft's Peter Lee: Generative AI could help doctors be more human

Wildfire smoke exposes gaps in outdoor worker protections

Group opposing PBM reform sets lobbying record

Guidelines to prevent youth baseball injuries need more muscle

Startup Neumora takes a novel depression drug to Phase 3

hotspot

Key House panel plots a new health care package

The public health thinking behind the CDC’s new Covid guidance

Families look for replacement for GSK asthma drug Flovent

Readout Newsletter: BridgeBio, Akero, and human embryo models

Listen: Wegovy in the brain & pivotal Alzheimer's data

Medicare has a new plan to address drug shortages

focus

entertainment

leisure time

explore